Celgene Corporation (CELG)
News
| May 26 | 7 Biotech Stocks to Add to Your Portfolio Investor Place |
| May 25 | High Profitability and Low Valuation for Gilead Fool |
| May 25 | @biotech $CYCC $CELG $BMY $REGN $PFE #ASCO12 checklist **All good names. I only focus on under $4 stocks though. Bouncier! ;=) by Urbane_Gorilla |
| May 25 | @Urbane_Gorilla http://stks.co/3z5t $CYCC $CELG $BMY $REGN $PFE #ASCO12 checklist by biotech |
| May 23 | How I rolled the short side of my diagonal spreads to June http://stks.co/3xhz $AAPL $FFIV $RVBD $BRCM $CELG $POT $YNDX $MON by monthlyspreads |
| May 23 | $CELG http://stks.co/3wmz Bounced nicely off the 200sma.If it can clear the recent high,I think it can get to the 50 sma at 75 by ACInvestorBlog |
| May 21 | The Definitive Biotech ETF Guide (IBB, XBI, FBT) Benzinga |
| May 21 | $CELG under a lot of pressure lately; trying to firm up at 200-day SMA by Kenshreve |
| May 19 | $celg Forget about 200SMA support. Here's the fundy: ASCO in early June, Pomalidomide in FDA hands, Apremilast soon to be the new Rev. by ForexChemist |
| May 18 | Top NASDAQ winners in pre-market: $YHOO $EXPE $MRVL $MAT $BIIB $WFM $ESRX $VRTX $BMC $TXN $SHLD $INFY $CELG $KLAC $DTV by abubnic |
| May 18 | S&P 500 Annual Meeting Calendar, Week of May 21 - June 15 |
| May 18 | 4 High-Growth Biotech Stocks With Negative Receivable Trends |
Profile
Exchange: NASDAQGS Sector: Healthcare Industry: Biotechnology
Celgene Corporation is a manufacturer of drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are Thalamid (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum ("ENL"), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid (lenalidomide), for which the company has received FDA and EMEA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both Thalamid and Revlimid are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Celgene Corporation has strategic collaboration with Acceleron Pharma, Inc. The company was founded in 1980.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Celgene Corporation is up 15.06% over the last year vs S&P 500 Total Return up 1.18%, Amgen up 18.79%, and Gilead Sciences up 22.58%.
- CELG Total Returns
- ^SPXTR Total Returns
- AMGN Total Returns
- GILD Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these CELG related companies
Pro Strategies Featuring CELG
Did Celgene Corporation make it into our Pro Portfolio Strategies?
CELG Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other CELG Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CELG | 68.90 | -1.01 | -1.44% | 30.23B |
| CEL | 7.55 | -0.07 | -0.92% | 751.07M |
| COP | 52.11 | -0.03 | -0.06% | 66.68B |
| COOL | 2.08 | +0.02 | +0.97% | 85.97M |
| COO | 85.53 | -0.21 | -0.24% | 4.093B |
| CONN | 17.71 | -0.04 | -0.23% | 566.19M |
| CONG | 50.80 | +0.04 | +0.08% | |
| COMV | 1.74 | +0.00 | +0.00% | 47.87M |
| COLM | 48.90 | +0.24 | +0.49% | 1.649B |
| COLB | 18.13 | -0.11 | -0.60% | 719.22M |
